文献速递创伤骨科骨质疏松与代谢性骨病

老年髋部骨折患者使用氨甲环酸是否安全?

Is tranexamic acid use in patients with a hip fracture safe?
PubMed 文献 · Bone Joint J · 2021-01-01

该研究基于丹麦南部地区2015至2017年连续队列的注册数据,纳入3097例65岁以上髋部骨折患者,比较围手术期使用氨甲环酸(TXA)与对照组的输血率、死亡率和血栓栓塞事件。结果显示TXA与较低输血率相关(调整RR 0.83),不增加30天和90天死亡率,且与较低血栓栓塞事件风险相关(30天RR 0.63;90天RR 0.72),结论认为在该人群中使用TXA是安全的。

要点

  • TXA组输血率27%,对照组31%,调整RR 0.83(95%CI 0.75-0.91)。
  • TXA不增加30天死亡率(调整HR 1.10,95%CI 0.88-1.39)和90天死亡率(调整HR 1.24,95%CI 0.93-1.66)。
  • TXA与较低血栓栓塞事件风险相关:30天RR 0.63(95%CI 0.42-0.93),90天RR 0.72(95%CI 0.52-0.99)。

核心结论

  • 老年髋部骨折患者使用TXA不增加死亡率,且与较低输血率和血栓栓塞事件风险相关,认为在该人群中使用TXA是安全的。

研究设计与样本

  • 连续队列研究,使用前瞻性收集的注册数据,纳入丹麦南部地区2015至2017年65岁以上髋部骨折患者,第一年为对照组,第二年围手术期引入TXA作为干预。
  • 共纳入3097例患者,对照组1558例,TXA组1539例。

主要发现

  • 对照组31%(477例)接受输血,TXA组27%(405例),调整RR 0.83(95%CI 0.75-0.91)。
  • 30天死亡率调整HR 1.10(95%CI 0.88-1.39),90天死亡率符合方案调整HR 1.24(95%CI 0.93-1.66),均无统计学显著增加。
  • TXA与较低血栓栓塞事件风险相关:30天RR 0.63(95%CI 0.42-0.93),90天RR 0.72(95%CI 0.52-0.99)。
  • 血红蛋白亚组分析:对照组中位下降17.7 g/L(IQR 11.3-27.3),符合方案TXA组中位下降17.7 g/L(IQR 9.7-25.8),组间差异p=0.060。

关键数值与推荐

  • 输血率:对照组31% vs TXA组27%,调整RR 0.83(95%CI 0.75-0.91)。
  • 30天死亡率调整HR 1.10(95%CI 0.88-1.39);90天死亡率符合方案调整HR 1.24(95%CI 0.93-1.66)。
  • 血栓栓塞事件30天RR 0.63(95%CI 0.42-0.93),90天RR 0.72(95%CI 0.52-0.99)。

临床怎么用

  • 对于65岁以上髋部骨折患者,围手术期使用TXA可降低输血率且不增加死亡风险,并可考虑用于减少血栓栓塞事件。

局限性

  • 本研究为单地区注册数据,第一年对照组与第二年TXA组为非随机历史对照,可能存在时间趋势偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To assess the safety of tranexamic acid (TXA) in a large cohort of patients aged over 65 years who have sustained a hip fracture, with a focus on transfusion rates, mortality, and thromboembolic events. METHODS: This is a consecutive cohort study with prospectively collected registry data. Patients with a hip fracture in the Region of Southern Denmark were included over a two-year time period (2015 to 2017) with the first year constituting a control group. In the second year, perioperative TXA was introduced as an intervention. Outcome was transfusion frequency, 30-day and 90-day mortality, and thromboembolic events. The latter was defined as any diagnosis or death due to arterial or venous thrombosis. The results are presented as relative risk (RR) and hazard ratio (HR) with 95% confidence intervals (CIs). RESULTS: A total of 3,097 patients were included: 1,558 in the control group and 1,539 in the TXA group.31% (n = 477) of patients had transfusions in the control group compared to 27% (n = 405) in the TXA group yielding an adjusted RR of 0.83 (95% CI 0.75 to 0.91). TXA was not associated with increased 30-day mortality with an adjusted HR of 1.10 (95% CI 0.88 to 1.39) compared to the control group as well as no association with increased risk of 90-day mortality with a per protocol adjusted HR of 1.24 (95% CI 0.93 to 1.66). TXA was associated with a lower risk of thromboembolic events after 30 days (RR 0.63 (95% CI 0.42 to 0.93)) and 90 days (RR 0.72 (95% CI 0.52 to 0.99)). A subanalysis on haemoglobin demonstrated a median 17.7 g/L (interquartile range (IQR) 11.3 to 27.3) decrease in the control group compared to 17.7 g/L (IQR 9.7 to 25.8) in the per protocol TXA group (p = 0.060 on group level difference). CONCLUSION: TXA use in patients with a hip fracture, was not associated with an increased risk of mortality but was associated with lower transfusion rate and reduced thromboembolic events. Thus, we conclude that it is safe to use TXA in this patient group. Cite this article: Bone Joint J 2021;103-B(3):449-455.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Viberg B, Gundtoft PH, Schønnemann JO, et al. Is tranexamic acid use in patients with a hip fracture safe? Bone Joint J. 2021. PMID: 33641426. doi:10.1302/0301-620X.103B3.BJJ-2020-1375.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。